Evidence map›Paper›PMID 42168200›Full record

ArticleNature communications2026

Macrophage ALDH2 drives immunotherapy resistance by silencing CXCL9 through metabolic-epigenetic crosstalk.

Huiying Fang, Jiazheng Sun, Qian Xiao, He Ren, Yuru Chen, Jiazhou Liu, Daqiang Song, Tiantian Chen, Linling Wu, Pin Wang and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Huiying Fang *Department of Breast and Thyroid Surgery, Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Jiazheng Sun *Department of Breast and Thyroid Surgery, Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Qian Xiao *Department of Breast and Thyroid, Women and Children's Hospital of Chongqing Medical University: Chongqing Health Center for Women and Children, Chongqing, China.
He Ren *Department of Oncological Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Yuru ChenDepartment of Breast and Thyroid Surgery, Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Jiazhou LiuDepartment of Breast and Thyroid Surgery, Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Daqiang SongDepartment of Breast and Thyroid Surgery, Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Tiantian ChenDepartment of Breast and Thyroid Surgery, Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Linling WuDepartment of Breast and Thyroid Surgery, Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Pin WangDepartment of Breast and Thyroid Surgery, Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Jian YueDepartment of Breast and Thyroid Surgery, Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Xiaoyu WangDepartment of Breast and Thyroid Surgery, Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Qilin YangDepartment of Breast and Thyroid Surgery, Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Yuxian WeiDepartment of Breast and Thyroid Surgery, Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Huimin DuDepartment of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Weiyan PengDepartment of Breast and Thyroid Surgery, Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Zhu QiuDepartment of Breast and Thyroid Surgery, Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Li ZhangBasic Research Laboratory of Traditional Chinese Medicine, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China.
Jingyuan WanDepartment of Pharmacology, Chongqing Medical University, Chongqing, China.
Tong LiuDepartment of Oncological Surgery, Harbin Medical University Cancer Hospital, Harbin, China. liutong@hrbmu.edu.cn.ORCID http://orcid.org/0000-0001-9234-1328
Guosheng RenDepartment of Breast and Thyroid Surgery, Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. rengs726@126.com.ORCID http://orcid.org/0000-0002-6416-8967
Hongzhong LiDepartment of Breast and Thyroid Surgery, Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. lihongzhong@cqmu.edu.cn.ORCID http://orcid.org/0000-0003-1136-5235

Funding

National Natural Science Foundation of China (National Science Foundation of China) 31420103915National Natural Science Foundation of China (National Science Foundation of China) 81472475National Natural Science Foundation of China (National Science Foundation of China) 82173166National Natural Science Foundation of China (National Science Foundation of China) 82372886National Natural Science Foundation of China (National Science Foundation of China) 82503734National Natural Science Foundation of China (National Science Foundation of China) 82573162Natural Science Foundation of Chongqing (Natural Science Foundation of Chongqing Municipality) CSTB2025NSCQ-LZX0151Natural Science Foundation of Chongqing (Natural Science Foundation of Chongqing Municipality) cstc2021jcyj-msxmX0015
6 · The paper itself

Abstract

The metabolic basis of tumor-associated macrophages (TAMs)-driven immune checkpoint blockade (ICB) resistance remains poorly understood. Here, in patients with immunotherapy-resistant cancer, we identify significant enrichment of TAMs marked by elevated aldehyde dehydrogenase 2 (ALDH2) expression. Myeloid-restricted ALDH2 ablation converts TAMs from a pro-tumorigenic phenotype to immunostimulatory regulators, concomitantly amplifying CD8

Indexed as

Aldehyde Dehydrogenase, MitochondrialDrug Resistance, NeoplasmEpigenesis, GeneticMacrophagesNeoplasmsTumor-Associated MacrophagesAnimalsCD8-Positive T-LymphocytesCell Line, TumorDisulfiramFemaleGene SilencingHumansImmune Checkpoint InhibitorsImmunotherapyMiceAldehyde Dehydrogenase, MitochondrialALDH2 protein, humanDisulfiramImmune Checkpoint Inhibitors

Identifiers

PMID42168200
PMCPMC13473648

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.